Bugworks Research Inc, a global biopharma startup designing novel broad-spectrum antibiotics, has announced the completion of $7.5 million financing, led by University of Tokyo Edge Capital (UTEC) Japan and Global Brain Corporation (Global Brain) Japan, along with Acquipharma Holdings, South-Africa. This investment enables Bugworks to complete Phase 1 studies for its GYROX series intravenous drug candidate, and advance an oral lead towards clinical development.